PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Analyze analyst forecasts for the company and compare them with competitors.
42.52K
Worse than AXSM's estimated revenue of 384.35M.
-8.50K
Worse than AXSM's estimated ebitda of 89.83M.
-1.41
Better than AXSM's estimated eps of -5.43.
-41.31M
Better than AXSM's estimated net income of -246.68M.
-8.50K
Worse than AXSM's estimated ebit of 87.89M.
1.58M
Better than AXSM's estimated sg&a expense of 567.06M.
View analysts' price targets and recommendations, and compare them with competitors.
$11.07
Higher upside than AXSM's upside of 56.00%.
Buy
Equal to AXSM's analyst recommendation of Buy.
Analyze DCF forecasts for the company and compare them with competitors.
1.03M
Worse than AXSM's revenue of 50.04M.
-9.97%
Worse than AXSM's revenue growth rate of 0.00%.
-33.41M
Better than AXSM's ebitda of -174.23M.
-3243.20%
Worse than AXSM's ebitda margin of -348.21%.
-34.10M
Better than AXSM's ebit of -179.80M.
-3311.07%
Worse than AXSM's ebit margin of -359.33%.
699.00K
Better than AXSM's depreciation of 5.56M.
108.91M
Worse than AXSM's total cash of 200.84M.
10573.79%
Better than AXSM's cash as percentage of revenue of 401.39%.
No Data
No DCF data available for this metric in the selected year.
No Data
No DCF data available for this metric in the selected year.
No Data
No DCF data available for this metric in the selected year.
No Data
No DCF data available for this metric in the selected year.
10.13M
Better than AXSM's accounts payable of 38.60M.
983.50%
Worse than AXSM's payables as percentage of revenue of 77.15%.
-366.00K
Worse than AXSM's capital expenditure of -702.11K.
-35.53%
Better than AXSM's capex as percentage of revenue of -1.40%.
4.99%
Better than AXSM's weighted average cost of capital (wacc) of 9.92%.
5.02%
Better than AXSM's cost of equity of 10.17%.
4.08%
Better than AXSM's cost of debt of 4.26%.
-0.23
Better than AXSM's beta of 1.25.
30.07M
Better than AXSM's diluted shares outstanding of 45.43M.
1.57M
Better than AXSM's total debt of 186.37M.
49.31M
Worse than AXSM's total equity of 4.18B.
50.89M
Worse than AXSM's total capital of 4.36B.
3.09%
Better than AXSM's debt weighting of 4.27%.
96.91%
Better than AXSM's equity weighting of 95.73%.
-32.98M
Better than AXSM's ebiat of -190.02M.
-28.05M
Better than AXSM's unlevered free cash flow of -201.72M.
2.00%
Equal to AXSM's long-term growth rate of 2.00%.
No Data
No DCF data available for this metric in the selected year.
No Data
No DCF data available for this metric in the selected year.
-71.33M
Worse than AXSM's net debt of -199.82M.
71.33M
Worse than AXSM's equity value of 6.33B.
2.37
Worse than AXSM's equity value per share of 139.31.